Meet Our Talented Founders Team
The founders of Glyx Therapeutics bring together complementary expertise in medicinal chemistry, neurobiology, and biotech entrepreneurship to address one of the most challenging targets in neurodegeneration: the tau protein.
Fabrice Beauchêne
CEO
Pr Anne Wadouachi
CSO
Damien Dessis
Business Advisor
Stéphane Milot
CFOMeet Our Scientific Board Members
The founders of Glyx Therapeutics bring together complementary expertise in medicinal chemistry, neurobiology, and biotech entrepreneurship to address one of the most challenging targets in neurodegeneration: the tau protein.
Marc Tiechmann
Neurologist
Pr Patricia Albanese
Professor of Cell Biology at the University of Paris-Est Créteil (UPEC)
Thibaud Lebouvier
Neurologist
Pr Fabrice Allain
Professor of Glycobiology at University of LilleistMeet Our Talented Scientific Team
The scientific team at Glyx Therapeutics unites deep expertise across neurobiology, medicinal chemistry, translational research, and neurodegeneration drug development. Together, the team designs and advances first-in-class anionic lipidic oligosaccharides engineered to target the tau protein.
Ajitha Thuraisamy PhD
Pre-Clinical Project Manager
Louis Genies
R&D Chemical Engineer-
Innovative R&D
-
Tauopathies
-
Sustainable Chemistry
-
Pharmaceutical Research
-
Biotechnology Innovations
-
Alzheimer's Disease
-
Innovative R&D
-
Tauopathies
-
Sustainable Chemistry
-
Pharmaceutical Research
-
Biotechnology Innovations
-
Alzheimer's Disease
Partner with Glyx Tx
Connect with our team to collaborate on first-in-class tau-targeting therapies for Alzheimer’s disease and rare tauopathies.
